- Company
- Takeda rejoins KRPIA after 5 years
- by Eo, Yun-Ho Nov 24, 2020 09:02am
- Takeda Pharmaceuticals Korea is returning to Korean Research-based Pharmaceutical Industry Association (KRPIA). The pharmaceutical industry sources recently reported Takeda has officially joined KRPIA as a member company. The company is gaining back its member company status as well. The KRPIA membership was inherited from Shire Phar
- Company
- An employee at drug company earns average KRW 41M
- by Chon, Seung-Hyun Nov 24, 2020 09:02am
- Apparently, the government statics say the average annual salary of the South Korean pharmaceutical industry is 41.4 million won. It was just shy of the general industry average. Depending on the pharmaceutical companies, some had average salary gap over 10 million among their employees. A university undergraduate’s average salary started from
- Company
- Daewoong succeeded in evading patent for Belkyra
- by Kim, Jin-Gu Nov 24, 2020 09:01am
- Daewoong once again succeeded in patent evasion of 'Belkyra (Deoxycholic acid)', an injection for improving submandibular fat. The original company, Allergan, tried to defend itself through 'divisional application' but failed. According to the pharmaceutical industry on the 23rd, the Intellectual Property Trial and Appeal Board recen
- Company
- Will Sanofi's CHC division become an opportunity for growth?
- by Nov 24, 2020 09:00am
- Sanofi began to gain attention afterward as Sanofi started to incorporate the independent consumer healthcare (CHC) division. Sanofi declared that the CHC division became an independent corporation from last year. CEO Paul Hudson, who took office in September last year, mentioned CHC's strategy for an independent corporation in December of
- Company
- "TNF blockers in rheumatoid arthritis is a symbol of trust"
- by Eo, Yun-Ho Nov 20, 2020 06:14am
- A tumor necrosis factor (TNF)-α inhibitor was a game changer for the rheumatoid arthritis (RA) treatment scene. An autoimmune disease RA, which causes break down in joints and bone tissues with abnormal immune reaction, has prevalence rate in female patients approximately 0.3 percent to 1 percent higher than male patients. According
- Company
- Protecting labor rights in multinational company spinoff
- by Nov 20, 2020 06:12am
- The multinational pharmaceutical companies in South Korea came under fire after they started restructuring and downsizing unilaterally and the experts are urging for the labors’ rights to participate and choose should to be secured. On Nov. 18, a member of the National Assembly Environment and Labor Committee and Democratic Party Lawmaker
- Company
- Bridge plans to establish follow-up development of BBT-877
- by Chon, Seung-Hyun Nov 20, 2020 06:11am
- Bridge Biotherapeutics announced on the 17th that it will establish a follow-up development and business strategy for BBT-877, which was recently returned from Boehringer Ingelheim, within the first half of next year. Bridge Biotherapeutics introduced research and development strategies at an online IR briefing for investors on this day. B
- Company
- Zejula for ovarian cancer gets close to 4th-line coverage
- by Eo, Yun-Ho Nov 19, 2020 06:14am
- An anticancer therapy for ovarian cancer Zejula is at the last threshold to win the reimbursement expansion. According to pharmaceutical industry sources, Takeda Pharmaceutical has recently initiated the drug pricing negotiation with the National Health Insurance Service (NHIS) on a poly ADP-ribose polymerase (PPARP) inhibitor Zejula’s
- Company
- SGLT-2 inhibitor, effective for patients with kidney disease
- by Nov 19, 2020 06:10am
- SGLT-2 inhibitors, developed as a treatment for diabetes, are further expanding their indications. It has proven its protective effect beyond simple cardiovascular safety, and recently, data proving the benefit of kidney disease is accumulating. In patients with type 2 diabetes, SGLT-2 inhibitors prevented the deterioration of renal function,
- Company
- Game changer Spravato first novel antidepressant in 30 years
- by Nov 19, 2020 06:10am
- For the first time in three decades, a novel antidepressant has been released in South Korea. Although the drug would be able to provide new treatment opportunity to patients with severe depression through a new mechanism of action, the patients may face high barrier in convenience and pricing. On Nov. 17, Janssen Korea convened a press
